Some Benefits for Decompressive Craniectomy in TBI

This article originally appeared here.
Share this content:
Some Benefits for Decompressive Craniectomy in TBI
Some Benefits for Decompressive Craniectomy in TBI

THURSDAY, Sept. 8, 2016 (HealthDay News) -- For patients with traumatic brain injury and refractory elevated intracranial hypertension, decompressive craniectomy results in lower mortality than medical care, according to a study published online Sept. 7 in the New England Journal of Medicine.

Peter J. Hutchinson, Ph.D., from the University of Cambridge in the United Kingdom, and colleagues randomized 408 patients, aged 10 to 65 years, with traumatic brain injury and refractory elevated intracranial pressure to undergo decompressive craniectomy or receive ongoing medical care.

The researchers observed a significant between-group difference in the Extended Glasgow Outcome Scale (GOS-E) distribution (P < 0.001). GOS-E distributions at six months were: death, 26.9 versus 48.9 percent in the surgical group versus medical group; vegetative state, 8.5 versus 2.1 percent; lower severe disability, 21.9 versus 14.4 percent; upper severe disability, 15.4 versus 8.0 percent; moderate disability, 23.4 versus 19.7 percent; and good recovery, 4.0 versus 6.9 percent. The GOS-E distributions at 12 months were: death, 30.4 versus 52.0 percent; vegetative state, 6.2 versus 1.7 percent; lower severe disability, 18.0 versus 14.0 percent; upper severe disability, 13.4 versus 3.9 percent; moderate disability, 22.2 versus 20.1 percent; and good recovery, 9.8 versus 8.4 percent.

"At six months, decompressive craniectomy in patients with traumatic brain injury and refractory intracranial hypertension resulted in lower mortality and higher rates of vegetative state, lower severe disability, and upper severe disability than medical care," the authors write.

Abstract
Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »